Skip to content
411 PRESS
WarningRecall #D-0503-2026Drug / Pharmaceutical

Wells Pharma of Houston LLC Recalls fentaNYL Citrate Injectable Solution

Wells Pharma of Houston LLC · Class II — Moderate Risk

Assorted pharmaceutical pills and tablets — representative photo for FDA drug recall
An assortment of pharmaceutical pills (representative file photo). Specific recalled product: see recall details below. Photo: Michael Nutt / Wikimedia Commons (CC BY-SA 2.0).

Product Description

fentaNYL Citrate Injectable Solution, NARCOTIC, Cii, 1000 mcg/100 mL (10 mcg per mL), 100 mL bag, Wells Pharma in Houston, NDC 73702-202-02.

Reason for Recall

cGMP deviations.

FDA Classification

Class II — Moderate Risk

A situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.

Distribution

U.S. Nationwide.

Remedy

Consumers should stop using this product. Contact the recalling firm for further instructions regarding this product.

411 Press Analysis

The FDA classified this recall as Class II, indicating the pharmaceutical product may cause temporary health problems or poses a slight threat of a serious nature. Wells Pharma of Houston LLC initiated the recall on April 1, 2026 affecting 4,030 IV Bags. cGMP deviations. The product was distributed in U.S. Nationwide. Consumers should check their purchases and discontinue use of any affected product. Contact Wells Pharma of Houston LLC for further instructions.

Independent news on labor, safety, and accountability.